Qelbree, a medication for treating absence seizures in individuals with epilepsy, was approved by the U.S. Food and Drug Administration (FDA) in December 2020 [1]. It became available for prescription in early 2021 [2].
When did Qelbree become commercially available?
Qelbree was launched in the U.S. market following its FDA approval in late 2020 [1][2]. This means it became available to patients and healthcare providers for prescription shortly thereafter, during the first quarter of 2021 [2].
What is Qelbree used to treat?
Qelbree is indicated for the treatment of partial-onset seizures in individuals with epilepsy who are 12 years of age and older [1]. It is a prescription medication and is intended for use as an adjunctive therapy, meaning it is taken in addition to other epilepsy medications [1].
How does Qelbree work?
The exact mechanism by which Qelbree works to treat partial-onset seizures is not fully understood [1]. However, it is believed to involve modulating the activity of vesicular glutamate transporter 2 (VMAT2) in the brain, which plays a role in the transport of neurotransmitters [1].
What are the potential side effects of Qelbree?
Common side effects associated with Qelbree include somnolence (drowsiness), decreased appetite, fatigue, nausea, vomiting, and difficulty sleeping (insomnia) [1]. In some cases, Qelbree has been associated with suicidal behavior and ideation, and a boxed warning is included on its labeling regarding this risk [1]. Patients and caregivers should be aware of and monitor for any changes in mood, behavior, or thoughts of self-harm [1].
Are there any risks associated with Qelbree?
Beyond the risk of suicidal behavior and ideation, Qelbree may also cause or worsen depression [1]. Patients who experience these symptoms should seek medical attention immediately [1]. Additionally, Qelbree can cause a reduction in blood pressure and heart rate, and patients with known cardiovascular conditions should discuss this with their doctor before starting treatment [1].
What is the generic name for Qelbree?
The active ingredient in Qelbree is tricaglide [1].
Are there other medications for partial-onset seizures?
Yes, numerous other medications are available for the treatment of partial-onset seizures in epilepsy, with varying mechanisms of action and side effect profiles [3]. These include medications like levetiracetam, lacosamide, brivaracetam, and many others. The choice of medication depends on individual patient factors, seizure type, and response to treatment [3].
What is the pricing and insurance coverage for Qelbree?
Information regarding the specific pricing and insurance coverage for Qelbree can vary [4]. Patients are advised to check with their insurance provider or the manufacturer for details on out-of-pocket costs, co-pay assistance programs, or patient support services [4].
When does the patent for Qelbree expire?
Information on the patent expiry for Qelbree is available through specialized databases. DrugPatentWatch.com provides comprehensive patent information for pharmaceuticals [5].
Who manufactures Qelbree?
Qelbree is manufactured by Supernus Pharmaceuticals, Inc. [1].
*
**Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214427s000lbl.pdf
[2] https://www.supernus.com/news-releases/news-release-details/supernus-pharmaceuticals-announces-fda-approval-qelbree-delivers-new-adjunctive-treatment-option-partial-onset-seizures-epilepsy
[3] https://www.epilepsy.com/treatment/anti-seizure-medications
[4] https://www.qelbree.com/
[5] https://drugpatentwatch.com/